Skip to main content
SpringerLink
Log in

Lanreotide 60 mg, a Longer-Acting Somatostatin Analog: Tumor Shrinkage and Hormonal Normalization in Acromegaly

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Background: Somatostatin analogues are nowadays the milestone in the medical treatment of acromegaly. We evaluated the effects of a new 60 mg longer-acting formulation of lanreotide (LAN60) on GH/IGF-I levels and tumor size. Patients: Twenty-one acromegalics entered a prospective monocentric open study. Eight were consecutive “de novo” patients (group I). Thirteen patients sensitive to SA (GH levels < 2.5 μg/l and/or IGF-I normalization on chronic LAN 30 mg (LAN30) treatment) were switched to LAN60 (group II). Protocol: LAN60 was administered IM for 6 cycles at 28 day intervals. In group I when GH/IGF-I remained pathological, the intervals were shortened to 21 days for the last three cycles. Controls: GH/IGF-I at the end of the 1st, 3rd and 6th cycle; MRI at the end of the study in all patients in group I bearing an adenoma. Results: Group I. GH (p = 0.00638, below 2.5 μg/l in two patients) and IGF-I (p = 0.0289, normalized in 5) significantly decreased. In one of two patients shortening the LAN60 schedule was more effective in suppressing GH/IGF-I. Group II. No change in GH and IGF-I levels was observed with the administration of LAN60, instead of LAN30. On LAN60 GH remained below 2.5 μg/l in 8/10 patients and IGF-I normal in 11/11 patients that had attained those values on LAN30. Tumor markedly shrank (23% to 64% vs basal), from 1400 (664–1680) mm3 to 520 (500–960) mm3 (median, interquartile, p = 0.0218) in all the 5 evaluable patients. Conclusion: LAN60 is a very effective and longer-lasting formulation for the treatment of acromegaly. A closer administration schedule might achieve greater efficacy. Its effectiveness in shrinking tumor opens new perspectives in the therapy of acromegaly.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless W. SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982;3:1133–1140.

    Google Scholar 

  2. Greenman Y, Melmed S. Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J Clin Endocrinol Metab 1994;78:398–403.

    Google Scholar 

  3. Sassolas G, Khalfallah Y, Chayvialle JA, Cohen R, Merabet S, Casez JP, Calvet P, Cabrera P. Effects of the somatostatin analog BIM 23014 on the secretion of growth hormone, thyrotropin, and digestive peptides in normal men. J Clin Endocrinol Metab 1989;68:239–246.

    Google Scholar 

  4. Heron I, Thomas F, Dero M, Poutrain J, Henane S, Catus F, Kuhn JM. Treatment of acromegaly with sustained-release lanreotide, a new somatostatin analog. Presse Med 1993; 22:526–531.

    Google Scholar 

  5. Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC. Depot long-acting somatostatin analog (Sandostatin LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab 1995;80:3267–3272.

    Google Scholar 

  6. Melmed S, Jackson I, Kleinberg D, Klibanski A. Current treatment guidelines for acromegaly. J Clin Endocrinol Metab 1998;83:2646–2652.

    Google Scholar 

  7. Robbins RJ. Depot somatostatin analogs—A new first line therapy for acromegaly. J Clin Endocrinol Metab 1998;82: 15–17.

    Google Scholar 

  8. Lancranjan J, Bruns C, Grass P, Jacquet P, Jervell J, Kendall-Taylor P, Lamberts SWJ, Marbach P, Orskov H, Pagani G, Sheppard M, Simionescu L. Sandostatin-LAR: A promising therapeutic tool in the management of acromegalic patients. Metabolism 1996;45:67–71.

    Google Scholar 

  9. Johnson MR, Chowdrey HS, Thomas F, Grint C, Lightman SL. Pharmacokinetics and efficacy of the long-acting somatostatin analogue somatuline in acromegaly. Eur J Endocrinol 1994;130:229–234.

    Google Scholar 

  10. Morange I, De Boisvilliers F, Chanson P, Lucas B, DeWailly D, Catus F, Thomas F, Jaquet P. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab 1994;79:145–151.

    Google Scholar 

  11. Al-Maskari M, Gebbie J, Kendall-Taylor P. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly. Clin Endocrinol (Oxf) 1996;45:415–421.

    Google Scholar 

  12. Giusti M, Gussoni G, Cuttica CM, Giordano G. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: Six-month report on an Italian multicenter study. J Clin Endocrinol Metab 1996;81:2089–2097.

    Google Scholar 

  13. Caron P, Morange-Ramos I, Cogne M, Jaquet P. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 1997; 82:18–22.

    Google Scholar 

  14. Colao A, Marzullo P, Ferone D, Marino V, Pivonello R, Di Somma C, Di Sarno A, Giaccio A, Lombardi G. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. J Endocrinol Invest 1999;22:40–47.

    Google Scholar 

  15. Suliman M, Jenkins R, Ross R, Powell T, Battersby R, Cullen DR. Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide. J Endocrinol Invest 1999;22:409–418.

    Google Scholar 

  16. Attanasio R, Barausse M, Cozzi R. GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide. J Endocrinol Invest 2001;24:209–216.

    Google Scholar 

  17. Newman CB. Medical therapy of acromegaly. Endocrinol Metab Clin N Amer 1999;28:171–190.

    Google Scholar 

  18. Barkan AL, Lloyd RV, Chandler WF, Hatfield MK, Gebarski SS, Kelch RP, Beitins IZ. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201–995: Shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 1988;67:1040–1048.

    Google Scholar 

  19. Barkan AL, Halasz I, Dornfeld KJ, JAffe CA, Friberg RD, Chandler WF, Sandler HM. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab 1997; 82:3187–3191.

    Google Scholar 

  20. Baldelli R, Ferretti E, Jaffrain-Rea ML, Iacobellis G, Minniti G, Caracciolo B, Moroni C, Cassone R, Gulino A, Tamburrano G. Cardiac effects of slow-release lanreotide, a slowrelease somatostatin analog, in acromegalic patients. J Clin Endocrinol Metab 1999;84:527–532.

    Google Scholar 

  21. Colao A, Marzullo P, Vallone G, Giaccio A, Ferone D, Rossi E, Scamaltino F, Lombardi G. Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. Clin Endocrinol (Oxf) 1999; 51:611–618.

    Google Scholar 

  22. Gasperi M, Battista C, Cannavò S, Ciccarelli E, Cozzi R, Mariotti S, Martini C, Pagani G, Paoletta A, Ballabio M. Preliminary data on the 3-month efficacy of lanreotide 60 mg in patients with active acromegaly. J Endocrinol Invest 2000;23(Suppl. to n. 6):28 (Abstract 86).

    Google Scholar 

  23. Pedroncelli AM, Montini M, Gianola D, Pagani MD, Albani G, Dallabonzana D, Pagani G. Octreotide LAR as first line therapy in acromegaly: Preliminary results. Pituitary 2000; 3:20 (OC16 Abstract).

    Google Scholar 

  24. Ahmed S, Elsheikh M, Stratton IM, Page RCL, Adams CBT, Wass JAH. Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf) 1999;50:561–567.

    Google Scholar 

  25. Fahlbusch R, Honegger J, Buchfelder M. Surgical management of acromegaly. Endocrinol Metab Clin N Amer 1992; 21:669–692.

    Google Scholar 

  26. Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL. Octreotide as primary treatment for acromegaly. J Clin Endocrinol Metab 1998;83:3034–3040.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Niguarda Hospital, Italy

    Renato Cozzi

  2. Division of Endocrinology, Niguarda Hospital, Italy

    Michela Barausse & Roberto Attanasio

  3. Division of Neuroradiology, Niguarda Hospital, Italy

    Maurizio Sberna

  4. Division of Neurosurgery, Neurologic Institute Carlo Besta, Milan, Italy

    Alessandro Lodrini, Angelo Franzini & Giovanni Lasio

Authors
  1. Renato Cozzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michela Barausse
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maurizio Sberna
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alessandro Lodrini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Angelo Franzini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Giovanni Lasio
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Roberto Attanasio
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cozzi, R., Barausse, M., Sberna, M. et al. Lanreotide 60 mg, a Longer-Acting Somatostatin Analog: Tumor Shrinkage and Hormonal Normalization in Acromegaly. Pituitary 3, 231–238 (2000). https://doi.org/10.1023/A:1012832230598

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1012832230598

Search

Navigation